Lilly's Covid-19 partner AbCellera is taking a new antibody into the clinic in the hopes it can tackle all variants

Max Gelman

Senior Editor

As the virus behind the Covid-19 pandemic continues to mutate into several variants of concern, the company behind Eli Lilly’s bamlanivimab antibody treatment is looking …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly's Covid-19 partner AbCellera is taking a new antibody into the clinic in the hopes it can tackle all variants

Max Gelman

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Lil­ly's Covid-19 part­ner Ab­Cellera is tak­ing a new an­ti­body in­to the clin­ic in the hopes it can tack­le all vari­ants

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Lilly's Covid-19 partner AbCellera is taking a new antibody into the clinic in the hopes it can tackle all variants